Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)

Authors
Category Primary study
JournalCancer Research
Year 2018
This article has no abstract
Epistemonikos ID: 1af10c5d1c82272b0a755f015ce285eac3c07b83
First added on: Feb 09, 2025